Meeting
2022 ASCO Annual Meeting
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Authors
Sebastian Grosicki
Department of Hematology and Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
Sebastian Grosicki , Jacob Crafoord , Youngil Koh , Darrel White , Ulf-Henrik Mellqvist , Eric Leip , Arthur Kudla , Gregory Finn , Łukasz Pruchniewski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Plasma Cell Disorders
Clinical Trial Registration Number
NCT05020236
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8074)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8074
Abstract #
TPS8074
Poster Bd #
494a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
MagnetisMM-6: An open-label, multicenter, randomized phase 3 study of elranatamab + daratumumab + lenalidomide (EDR) versus daratumumab + lenalidomide + dexamethasone (DRd) in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM).
First Author: Sebastian Grosicki
Poster
2022 ASCO Annual Meeting
Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.
First Author: Anupama Deepa Kumar
Poster
2013 ASCO Annual Meeting
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.
First Author: David Samuel DiCapua Siegel
Poster
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Sagar Lonial